This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
In Silico Modelling for Orally Inhaled Drug Development (OINDP)
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Sustainable Propellants and Bioequivalence Innovation in OINDPs
Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Intranasal Delivery of Monoclonal Antibodies via Dry Powder
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Systemic Nasal Drug Delivery for CNS Diseases and Beyond
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions